Shows overattenuation of D46/cp/ΔM2-2 vaccine in RSV-seronegative children, indicating safety concerns.
The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but over-attenuated in 12 to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6 to 24-month-old RSV-seronegative children (dose: 105 PFU).
No takes yet. Share an insight, caveat, or question.
Karron et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: